Tools
Tools
Maguire, A, Mooney, C, Flynn, G, Ferguson, Y, O'Keane, V, O'Rourke, D, McMonagle, T, Heaton, R, Phillips, S, Hargreaves, IP, Gill, M and Hargreaves, A (2021) No Effect of Coenzyme Q10 on Cognitive Function, Psychological Symptoms, and Health-related Outcomes in Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 41 (1). pp. 53-57. ISSN 0271-0749
|
Text
No Effect of Coenzyme Q10 on Cognitive Function, Psychological Symptoms, and Health-related Outcomes in Schizophrenia and Schizoaffective Disorder.pdf - Accepted Version Download (336kB) | Preview |
Abstract
Background: Cognitive impairments, negative symptoms, affective symptoms, and low energy are highly prevalent features of schizophrenia. Mitochondrial dysfunction has been hypothesized as one of the numerous factors to underlie the manifestation of these symptoms. The objective of this study was to evaluate whether Coenzyme Q10 (CoQ10) has a role in the treatment of schizophrenia and schizoaffective disorder.
Methods: A double-blind, randomized, placebo-controlled trial was conducted to assess the effects of CoQ10 supplementation (300 mg/day) on the coprimary outcomes of attention and working memory performance after 3 and 6 months. Secondary outcomes included plasma CoQ10 levels, mitochondrial function, energy, depression, anxiety, negative symptoms, and quality of life.
Findings: In total, 72 patients were randomized to intervention groups. Overall, there was no effect of CoQ10 supplementation on the primary outcome measures at 3 or 6 months. Further, with the exception of plasma CoQ10 levels, CoQ10 supplementation also had no effect on the secondary outcomes. At 3 months, CoQ10 concentration was significantly higher in the CoQ10 group (3.85 μg/mL) compared with placebo (1.13 μg/mL); this difference was not present at 6 months.
Conclusions: The results of the study suggest that CoQ10 supplementation at 300 mg/day for 6 months is unlikely to be beneficial for cognitive, psychological and health-related outcomes in schizophrenia and schizoaffective disorder. However, a number of limitations including low adherence, modest sample size, and attrition, likely reduce estimates of effects. As such, results should be considered preliminary.
| Item Type: | Article |
|---|---|
| Additional Information: | This is the author accepted manuscript after peer review not the version of record. |
| Uncontrolled Keywords: | 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Pharmacy & Biomolecular Sciences |
| Publisher: | Lippincott, Williams & Wilkins |
| Date Deposited: | 02 Dec 2020 10:54 |
| Last Modified: | 31 Jan 2022 00:50 |
| DOI or ID number: | 10.1097/JCP.0000000000001330 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/14114 |
 |
View Item |